文献速递眼底病与葡萄膜炎

长期使用大麻与术后增生性玻璃体视网膜病变风险

Long-Term Cannabis Use and Risk of Postoperative Proliferative Vitreoretinopathy.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项回顾性队列研究基于多中心电子健康记录(2005年2月1日至2025年2月1日),经倾向评分匹配后每组各1193例,比较伴大麻相关障碍且尿或血大麻检测阳性的视网膜脱离修复患者与无大麻使用记录的对照组。6个月时,大麻使用组发生增生性玻璃体视网膜病变的风险降低(25例事件[2.10%] vs 52例事件[4.36%];RR,0.48;95%CI,0.30-0.77;P=.002),需复杂视网膜脱离修复的风险也降低(37例[3.10%] vs 60例[5.03%];RR,0.62;95%CI,0.41-0.92;P=.02),1年时两结局结果相似。作者认为绝对差异较小,保护性关联可能源于使用人群而非大麻本身,需干预试验控制混杂因素。

要点

  • 匹配后每组1193例,6个月增生性玻璃体视网膜病变25例(2.10%)vs 52例(4.36%),RR 0.48(95%CI 0.30-0.77;P=.002)。
  • 6个月需复杂视网膜脱离修复37例(3.10%)vs 60例(5.03%),RR 0.62(95%CI 0.41-0.92;P=.02),1年时两结局结果相似。
  • 作者指出绝对差异小,保护性关联可能源于使用人群而非大麻本身,需干预试验控制混杂因素。

核心结论

  • 伴大麻使用的最初视网膜脱离修复患者较无大麻使用记录的匹配患者发生增生性玻璃体视网膜病变及需后续复杂视网膜脱离修复的可能性更低,但率绝对差异小。
  • 作者认为该保护性关联可能源于使用大麻的人群而非大麻本身,提示大麻使用可能在减少增生性玻璃体视网膜病变中起作用,需干预试验控制混杂因素。

研究设计与样本

  • 回顾性队列研究,使用多中心研究网络电子健康记录,数据提取时段为2005年2月1日至2025年2月1日。
  • 纳入接受初次视网膜脱离修复(平坦部玻璃体切除术伴或不伴巩膜扣带、初次巩膜扣带或充气性视网膜固定术)的患者。
  • 暴露为合并大麻相关障碍且尿或血大麻检测阳性,对照为无大麻使用记录者;排除有增生性糖尿病视网膜病变病史或随访不足6个月者。
  • 经倾向评分匹配后每组各1193例;平均(SD)年龄53.2(16.1)岁;男性1662例(69.7%),女性641例(26.9%),83例(3.5%)性别未知。

主要发现

  • 6个月时,任何方法修复视网膜脱离的伴大麻使用患者发生后续增生性玻璃体视网膜病变的风险降低:25例事件(2.10%)vs 52例事件(4.36%);RR,0.48;95%CI,0.30-0.77;P=.002。
  • 6个月时,伴大麻使用患者需复杂视网膜脱离修复的风险降低:37例(3.10%)vs 60例(5.03%);RR,0.62;95%CI,0.41-0.92;P=.02。
  • 1年时两结局结果相似。

关键数值与推荐

  • 6个月增生性玻璃体视网膜病变:大麻使用组25例事件(2.10%)vs 对照组52例事件(4.36%),RR 0.48(95%CI 0.30-0.77;P=.002)。
  • 6个月需复杂视网膜脱离修复:大麻使用组37例(3.10%)vs 对照组60例(5.03%),RR 0.62(95%CI 0.41-0.92;P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出绝对差异小。
  • 作者认为保护性关联可能源于使用大麻的人群而非大麻本身。
  • 作者指出需干预试验以控制混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proliferative vitreoretinopathy (PVR) is a major cause of retinal detachment (RD) repair failure, resulting in poor visual outcomes. Cannabis use continues to increase globally and may affect PVR development through its anti-inflammatory and neuroprotective properties, although this association remains unclear. OBJECTIVE: To assess the risk of developing PVR among patients with concomitant cannabis use who underwent primary RD repair. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study examined data from electronic health records for a multicenter research network extracted for the period February 1, 2005, to February 1, 2025. Participants were patients who underwent initial RD repair with pars plana vitrectomy (PPV) with or without scleral buckle (SB), primary SB, or pneumatic retinopexy. The records were used to identify patients diagnosed with concomitant cannabis-related disorder together with confirmatory testing of cannabis in urine or blood compared with a control group without documented use. Exclusion criteria were a history proliferative diabetic retinopathy or less than 6 months of follow-up. EXPOSURES: Primary RD repair and cannabis-related disorder. MAIN OUTCOME MEASURES: Relative risk (RR) of developing PVR and requiring a subsequent complex RD repair at 6 months and 1 year of follow-up. RESULTS: After propensity score matching, each cohort had 1193 patients. The mean (SD) age was 53.2 (16.1) years; 1662 were male (69.7%), 641 were female (26.9%), and for 83 patients (3.5%), the sex was unknown. At 6 months, patients with concomitant cannabis use with RD repaired by any method had a reduced risk of developing subsequent PVR (25 events [2.10%] vs 52 events [4.36%]; RR, 0.48; 95% CI, 0.30-0.77; P = .002) and requiring complex RD repair (37 [3.10%] vs 60 [5.03%]; RR, 0.62; 95% CI, 0.41-0.92; P = .02) when compared with controls. Similar results were observed at 1 year for both outcomes. CONCLUSIONS AND RELEVANCE: Patients who underwent initial repair for RD with concomitant cannabis use were less likely to develop PVR and require subsequent complex RD repair compared with matched patients without documented cannabis exposure; however, the absolute difference in rates was small. While this protective association noted with cannabis use could be due to the population using it rather than an effect of the cannabis itself, the findings suggest that cannabis use might have a role in reducing PVR development. Intervention trials would be needed to try to control for confounding factors.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Alshaikhsalama AM, Alsoudi AF, Mukhtar A, et al. Long-Term Cannabis Use and Risk of Postoperative Proliferative Vitreoretinopathy. JAMA Ophthalmol. 2025. PMID: 40608320. doi:10.1001/jamaophthalmol.2025.1851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。